CONTRAINDICATIONS SECTION.


CONTRAINDICATIONS. History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) During or within 14 days following the administration of monoamine oxidase inhibitors Hyperthyroidism Glaucoma Agitated states History of drug abuse Pregnancy (see Precautions) Nursing (see Precautions) Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines.

DOSAGE & ADMINISTRATION SECTION.


DOSAGE AND ADMINISTRATION. Dosage should be individualized to obtain an adequate response with the lowest effective dose. The usual adult dose is one tablet three times day 1/2 hour before meals. This tablet is scored to facilitate administering one half of the usual dosage for patients not requiring the full dose. Phentermine hydrochloride is not recommended for use in pediatric patients less than or equal to 16 years of age. Late evening medication should be avoided because of the possibility of resulting insomnia.

DESCRIPTION SECTION.


DESCRIPTION. Phentermine hydrochloride is sympathomimetic amine anorectic. Its chemical name is ,,-dimethylphenethylamine hydrochloride. The structural formula is as follows:Phentermine hydrochloride, USP is white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.Phentermine hydrochloride tablet, USP is available as an oral tablet containing mg of phentermine hydrochloride (equivalent to 6.4 mg of phentermine base). Each phentermine hydrochloride tablet also contains the following inactive ingredients: Corn Starch, Magnesium Stearate, NF, Microcrystalline Cellulose 102, NF, Stearic Acid, NF, FD&C Blue 1. chemical structure.

ADVERSE REACTIONS SECTION.


ADVERSE REACTIONS. The following adverse reactions are described, or described in greater detail, in other sections:- Primary pulmonary hypertension (see Warnings)- Valvular heart disease (see Warnings)- Effect on the ability to engage in potentially hazardous tasks (see Warnings)- Withdrawal effects following prolonged high dosage administration (see Drug Abuse and Dependence) The following adverse reactions to phentermine have been identified:. Cardiovascular. Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events.. Central Nervous System. Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis.. Gastrointestinal. Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.. Allergic. Urticaria.. Endocrine. Impotence, changes in libido.

CLINICAL PHARMACOLOGY SECTION.


CLINICAL PHARMACOLOGY Mechanism of Action Phentermine is sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and ll-amphetamine). Drugs of this class used in obesity are commonly known as anorectics or anorexigenics. It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved. Pharmacodynamics Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.. Pharmacokinetics Specific PopulationsRenal ImpairmentPhentermine was not studied in patients with renal impairment. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62%-85%. Exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment.

CLINICAL STUDIES SECTION.


CLINICAL STUDIES. In relatively short-term clinical trials, adult obese subjects instructed in dietary management and treated with anorectic drugs lost more weight on the average than those treated with placebo and diet.The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only fraction of pound week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an anorectic drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss. The natural history of obesity is measured over several years, whereas the studies cited are restricted to few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.

DRUG ABUSE AND DEPENDENCE SECTION.


DRUG ABUSE AND DEPENDENCE. Controlled Substance. Phentermine is Schedule IV controlled substance.. Abuse. Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including drug as part of weight reduction program.. Dependence. Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times than recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.

HOW SUPPLIED SECTION.


HOW SUPPLIED/STORAGE AND HANDLING. Phentermine Hydrochloride Tablet, USP is available as follows:Phentermine Hydrochloride Tablet, USP mg is supplied as blue and white mottled body shape tablets debossed K above bisect 67 on one side and plain on the other side.Bottles of 30, NDC 10702-067-03Bottles of 1000, NDC 10702-067-10Bottles of 5000, NDC 10702-067-05Store at 20 to 25 (68 to 77F) with excursion permitted between 15 to 30 (59 to 86 F) [See USP Controlled Room Temperature].Dispense in tight container as defined in the USP, with child-resistant closure (as required).Keep out of the reach of children.Manufactured by: KVK-Tech, Inc. 110 Terry Drive Newtown, PA 18940 Item ID 006177/03Manufacturers Code: 10702 11/16. image description.

INDICATIONS & USAGE SECTION.


INDICATIONS AND USAGE. Phentermine hydrochloride tablets are indicated as short-term (a few weeks) adjunct in regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity in patients with an initial body mass index greater than or equal to 30 kg/m 2, or greater than or equal to 27 kg/m in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). Below is chart of body mass index (BMI) based on various heights and weights.BMI is calculated by taking the patients weight, in kilograms (kg), divided by the patients height, in meters (m), squared. Metric conversions are as follows: pounds 2.2 kg; inches 0.0254 meters. The limited usefulness of agents of this class, including phentermine (see Clinical Pharmacology), should be measured against possible risk factors inherent in their use such as those described below.. Body Mass Chart.

MECHANISM OF ACTION SECTION.


Mechanism of Action Phentermine is sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and ll-amphetamine). Drugs of this class used in obesity are commonly known as anorectics or anorexigenics. It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved. Pharmacodynamics Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.. Pharmacokinetics Specific PopulationsRenal ImpairmentPhentermine was not studied in patients with renal impairment. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62%-85%. Exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment.

OVERDOSAGE SECTION.


OVERDOSAGE. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.. Acute Overdosage. Manifestations of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Overdosage of pharmacologically similar compounds has resulted in fatal poisoning usually terminates in convulsions and coma.Management of acute phentermine hydrochloride intoxication is largely symptomatic and includes lavage and sedation with barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine(R), CIBA) has been suggested on pharmacologic grounds for possible acute, severe hypertension, if this complicates overdosage.. Chronic Intoxication. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia. See Drug Abuse and Dependence.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.


PACKAGE LABEL.PRINCIPAL DISPLAY PANEL. 30 TabletsNDC 10702-067-03Phentermine Hydrochloride Tablets, USP CIV8 mgRx Only30 TabletsKVK-TECH, INC.1000 TabletsNDC 10702-067-10Phentermine Hydrochloride Tablets, USP CIV8 mgRx Only5000 TabletsKVK-TECH, INC.5000 TabletsNDC 10702-067-05Phentermine Hydrochloride Tablets, USP CIV8 mgRx Only1000 TabletsKVK-TECH, INC.. 30s label. 1000s label. 5000s label.

PHARMACODYNAMICS SECTION.


Pharmacodynamics Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

PHARMACOKINETICS SECTION.


Pharmacokinetics Specific PopulationsRenal ImpairmentPhentermine was not studied in patients with renal impairment. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62%-85%. Exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment.

PRECAUTIONS SECTION.


PRECAUTIONS. Information for Patients. Patients must be informed that phentermine hydrochloride is short-term (a few weeks) adjunct in regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity, and that coadministration of phentermine with other drugs for weight loss is not recommended (see Indications and Usage and Warnings).Patients must be instructed on how much phentermine to take, and when and how to take it (see Dosage and Administration). Advise pregnant women and nursing mothers not to use phentermine (see Precautions). Patients must be informed about the risks of use of phentermine (including the risks discussed in Warnings and Precautions), about the symptoms of potential adverse reactions and when to contact physician and/or take other action. The risks include, but are not limited to: Development of primary pulmonary hypertension (see Warnings) Development of serious valvular heart disease (see Warnings) Effects on the ability to engage in potentially hazardous tasks (see Warnings) The risk of an increase in blood pressure (see Warnings and Adverse Reactions) The risk of interactions (see Contraindications, Warnings, and Precautions/Drug Interactions) The patients must also be informed about the potential for developing tolerance and actions if they suspect development of tolerance (see Warnings) and the risk of dependence and the potential consequences of abuse (see Warnings, Drug Abuse and Dependence, and Overdosage). Tell patients to keep phentermine in safe place to prevent theft, accidental overdose, misuse or abuse. Selling or giving away phentermine may harm others and is against the law. Drug Interactions. Monoamine Oxidase InhibitorsUse of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis. AlcoholConcomitant use of alcohol with phentermine may result in an adverse drug reaction. Insulin and Oral Hypoglycemic MedicationsRequirements may be altered (see Warnings) Adrenergic Neuron Blocking DrugsPhentermine may decrease the hypotensive effect of adrenergic neuron blocking drugs. Carcinogenesis, Mutagenesis, Impairment of Fertility. Studies have not been performed with phentermine to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.. Pregnancy. Pregnancy Category XPhentermine is contraindicated during pregnancy because weight loss offers no potential benefit to pregnant woman and may result in fetal harm. minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to obligatory weight gain that occurs in maternal tissues during pregnancy. Phentermine has pharmacologic activity similar to amphetamine (d- and dll-amphetamine) (see Clinical Pharmacology ). Animal reproduction studies have not been conducted with phentermine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to fetus.. Nursing Mothers. It is not known if phentermine is excreted in human milk; however, other amphetamines are present in human milk. Because of the potential for serious adverse reactions in nursing infants, decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.. Pediatric Use. Safety and effectiveness in pediatric patients have not been established. Because pediatric obesity is chronic condition requiring long-term treatment, the use of this product, approved for short-term therapy, is not recommended.. Geriatric Use. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.. Renal Impairment. Phentermine was not studied in patients with renal impairment. Based on the reported excretion of phentermine in urine, exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment (see Clinical Pharmacology).

SPL UNCLASSIFIED SECTION.


Coadministration with Other Drug Products for Weight Loss. Phentermine hydrochloride tablets are indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended.. Primary Pulmonary Hypertension. Primary Pulmonary Hypertension (PPH) a rare, frequently fatal disease of the lungs has been reported to occur in patients receiving combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.. Valvular Heart Disease. Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.. Development of Tolerance, Discontinuation in Case of Tolerance. When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.. Effect on the Ability to Engage in Potentially Hazardous Tasks. Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving motor vehicle; the patient should therefore be cautioned accordingly.. Risk of Abuse and Dependence. Phentermine is related chemically and pharmacologically to amphetamine (d- and dll-amphetamine) and other related stimulant drugs have been extensively abused. The possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including drug as part of weight reduction program. See Adverse Reactions/Drug Abuse and Dependence and Overdosage. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.. Usage with Alcohol. Concomitant use of alcohol with phentermine may result in an adverse drug reaction.. Use in Patients with Hypertension. Use caution in prescribing phentermine for patients with even mild hypertension (risk of increase in blood pressure).. Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus. reduction in insulin or oral hypoglycemic medications in patients with diabetes mellitus may be required.

WARNINGS SECTION.


WARNINGS. Coadministration with Other Drug Products for Weight Loss. Phentermine hydrochloride tablets are indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended.. Primary Pulmonary Hypertension. Primary Pulmonary Hypertension (PPH) a rare, frequently fatal disease of the lungs has been reported to occur in patients receiving combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.. Valvular Heart Disease. Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.. Development of Tolerance, Discontinuation in Case of Tolerance. When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.. Effect on the Ability to Engage in Potentially Hazardous Tasks. Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving motor vehicle; the patient should therefore be cautioned accordingly.. Risk of Abuse and Dependence. Phentermine is related chemically and pharmacologically to amphetamine (d- and dll-amphetamine) and other related stimulant drugs have been extensively abused. The possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including drug as part of weight reduction program. See Adverse Reactions/Drug Abuse and Dependence and Overdosage. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.. Usage with Alcohol. Concomitant use of alcohol with phentermine may result in an adverse drug reaction.. Use in Patients with Hypertension. Use caution in prescribing phentermine for patients with even mild hypertension (risk of increase in blood pressure).. Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus. reduction in insulin or oral hypoglycemic medications in patients with diabetes mellitus may be required.